Is this Bright Idea 💡establishing my favorite pattern?

I will be keeping my eagle eye 👀 on this young stock again today... *Sponsored by Lifewater Media When I wrote to you yesterday, the tiny biotech Coeptis Therapeutic Holdings (Nasdaq: COEP) opened at $1.79.  I urged you to begin your research on the company “immediately, before this entry window closes.” Well, after an initial dip, the stock rode a fairly steady wave up all day, reaching $1.84 at the close and defying the NASDAQ’s 1.3% tumble. Although this wasn’t the banger I was hoping for yesterday, the uptrend line is a good sign as the stock is strengthening its baseline. Remember that this stock has only been [trading]( since Oct 31st, 2022, so it’s good to test its support level. Today, I’m keeping my 🦅eagle eye on this stock to see if this uptrend continues, and makes my favorite pattern of higher lows and higher highs. I don’t know about you, but I’ll take this healthy climb over a 1% loss any day. So has the window closed?I don’t think so…we’re still in the early innings here in my view, folks, so if you missed the entry yesterday, be sure to check out my full email below and see what you think. ******************** After Apple’s tremendous flop the other day (a $3,500 equivalent to Meta’s Oculus? Get outta here)... Another – much more exciting – tech stock came across my desk, and it looks like I’m not the only one with my eyes on it: Coeptis Therapeutic Holdings (Nasdaq: COEP) In the last few days, this tiny biotech stock has shot up by 24% and counting… Ultimately outperforming the NASDAQ by more than 2400% — But why? And, more importantly, is this the beginning of another MASSIVE RUN for the company? All signs say that it’s very possible. After all, since [going public]( in October 2022, COEP has delivered tremendous price action again and again: Back in December, we saw COEP pop by 80% in just over two weeks… March saw the stock making a healthy 60% climb in 12 short days (check these out on [TradingView]()… And just a few weeks ago, COEP came crashing out of the gate with a 104% run in just 24 days 👇. With numbers like that, I wasn’t surprised to discover that [Vanguard](, [Fidelity]( and [Citadel]( are already staking their claims. While Cambridge Investment Research [doubled its holdings](… And Tower Research Capital has ballooned its[stake by 1,688%](! But again — why is COEP capturing the attention of the big-league players? Because they could be completely redefining the future of cell therapy! If you’re not familiar with the term, it essentially boils down to placing new, healthy cells into the body to replace diseased or damaged ones as an alternative to more dangerous chemical treatments. The implications for the treatment of diseases like diabetes and cancer could be enormous. For example, this [study]( has found that up to 50% of cancer patients are killed by chemotherapy. Let that sink in for a moment — Now consider the fact that roughly [2 million people are diagnosed with cancer]( in the United States every year, with the CDC projecting these numbers [to grow significantly]( into 2050. Based on these projections, [Precedence Research]( has forecasted the market for cell therapy to also grow significantly stating, “The global cell therapy market was valued at US $10.35 billion in 2021 and it is expected to hit US $60.67 billion by 2030” (highlights added).  So who will lead the charge in the cell therapy space? Will it be Coeptis? Well, the company is positioning itself to be the one to do just that. In fact, their promise to revolutionize the medical field is so stunning that the University of Pittsburgh has [taken them on as a research partner]( to expedite the development of their treatments: While simultaneously tackling one of the biggest challenges in the cell therapy market — the [extreme shortage]( of skilled professionals in the field. By joining forces with the University of Pittsburgh, they’re bridging the gap between the academic world, where tomorrow’s doctors are being trained, and the biotech industry. This points to the stage being set for an entire generation of grads to have access to this game-changing research, and the opportunity to get hands-on experience with it before they enter the fray as medical professionals. They’re basically putting jet fuel in the engine to push widespread adoption of their cell therapy tech light-years ahead of the curve. But their sphere of influence goes beyond academia, with the [ongoing acquisition]( of Florida-based biotech firm VyGen-Bio further boosting the scope of their research capabilities. On top of that, they’ve also entered into a [binding agreement]( with Deverra Therapeutics, INC giving them the SOLE right to acquire the “NK Platform” which effectively trains “killer” cells to target cancer cells while IGNORING the cells that work for the patient’s immune system. By acquiring this proprietary technology, Coeptis is securing the exclusive rights to two FDA Investigational New Drug (IND) applications, two Phase 1 clinical trials to be exact. And these could give them the potential to modify their existing tech to target a whole range of chronic disorders beyond cancer… All of these opportunities combine to give COEP multiple shots on goal: Now, as impressive as COEP’s fundamentals are, I have to say in my opinion the technicals are even better. Check this out: I mean, when you’re looking at a small-cap stock, it rarely gets better than this — Company insiders are clearly willing to put their money where their mouth is, with 52.11% of shares in their hands… Folks, in my opinion, this is a critical factor when analyzing microcaps like this. Because when you’re sitting at a “low float” like you see here, even a small wave of bullish sentiment can produce the sort of 60%...80%...even 100% moves we’ve seen on COEP over the last 10 months. And let me tell you, sentiments are beyond bullish, with [some experts](, including [EF Hutton](, projecting a $10 price point for COEP: Even if the stock somehow trends towards the low end of this analysis – capping out at $4 instead of $10 – that would still mean a surge of around 127% from current levels. All in all, we’re looking at one heck of a gem here, with: - A low entry point (just $1.72 at this writing) - Price targets set at $10.00 (470% surge) - Minimal float (under 4%) - Bullish sentiment driven by multiple partnerships & acquisitions - Several clinical trials in the foreseeable future - Huge potential in a market set to climb to [$60B by 2030](. All this culminates in what could be a seemingly-perfect storm for stellar growth. Now, just because I love this stock doesn’t mean you should go in blindly. While I’m personally expecting to see some positive performance on COEP in the near future, doing your own research is absolutely critical — This is a rare gem, but you need to make sure you understand your risk, and the potential rewards that come along with it. Investing is risky and it is always the right decision to do your own investigation. I think you’ll agree with my opinion. And based on how quickly this stock is already moving… you could begin immediately, before this entry window closes. A great place to start would be [right here on the company’s website](. So take all the information in, do your due diligence, and see if this opportunity has a place in your portfolio! To Your Success, *Please see disclosures below PS. Text “RAGE” to (888) 404-5747 to get ALL of my latest HOT STOCK ideas before anyone else! --------------------------------------------------------------- Disclosures: RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Manage your email subscriptions.]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. If you have a current active subscription with Bullseye Trades you will need to contact us if you want to cancel your subscription. Opting out of emails does not remove you from your service at Bullseye Trades.